Congenital adrenal hyperplasia complicated by central precocious puberty: treatment with LHRH-agonist analogue.
Eight children with congenital adrenal hyperplasia and late initiation of corticosteroid treatment are included in the present study. Four of them received LHRHa treatment for the arrest of central precocious puberty, while the other four served as controls. The administration of LHRHa was effective in arresting the manifestations of puberty. The final height in the LHRHa-treated group was 158.2 +/- 7.3 cm (SDS -1.1 +/- 0.5) and did not differ from the target height of 158.9 +/- 6.5 cm (SDS -1.1 +/- 0.2), while the final height in the controls was 153 +/- 11 cm, a value significantly lower than their target height of 164.5 +/- 8.3 (SDS -0.6 +/- 0.7) with p < 0.05. The data showed that LHRHa is effective in arresting central precocious puberty and appears to improve final height, bringing it closer to that expected from the genetic potentials.
Dacou-Voutetakis
C
C
First Pediatric Department, Athens University, Greece.
Karidis
N
N
D000312:Adrenal Hyperplasia, Congenital / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000595:Amino Acid Sequence; D002675:Child, Preschool; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008969:Molecular Sequence Data; D011629:Puberty, Precocious / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D011761:Pyrrolidonecarboxylic Acid / Q000031:analogs & derivatives
C081916:pyroglutamyl-histidyl-tryptophyl--seryl-tyrosyl-tryptophyl-leucyl-arginyl-prolyl-glycinamide; D007987:Gonadotropin-Releasing Hormone; D007986:Luteinizing Hormone; D011761:Pyrrolidonecarboxylic Acid